Charles Kung Selected Research

mitapivat

11/2022	A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
1/2022	Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.
1/2021	AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes.
1/2021	The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
1/2021	Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy.
1/2019	Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
1/2019	Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
1/2017	AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles Kung Research Topics

Disease

5	Pyruvate Kinase Deficiency of Red Cells 01/2021 - 01/2017
4	Hemolytic Anemia 01/2021 - 12/2015
3	Anemia 01/2021 - 09/2017
3	Neoplasms (Cancer) 10/2020 - 09/2012
2	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2022 - 01/2019
2	Sickle Cell Anemia (Hemoglobin S Disease) 11/2022 - 01/2021
2	Headache (Headaches) 11/2022 - 01/2019
2	Hemolysis 01/2021 - 01/2019
1	Hypertension (High Blood Pressure) 11/2022
1	Leukocytosis (Pleocytosis) 01/2022
1	Iron Overload 01/2021
1	Thalassemia 01/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Necrosis 10/2020
1	Insulin Resistance 12/2019
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2017
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 07/2015
1	Hepatocellular Carcinoma (Hepatoma) 07/2015
1	Carcinogenesis 10/2012

Drug/Important Bio-Agent (IBA)

9	Pyruvate KinaseIBA 11/2022 - 10/2012
8	mitapivatIBA 11/2022 - 01/2017
5	Adenosine Triphosphate (ATP)IBA 01/2022 - 12/2015
2	2,3-Diphosphoglycerate (2,3 Bisphosphoglycerate)IBA 01/2022 - 09/2017
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 01/2019
2	EnzymesIBA 01/2021 - 01/2019
2	Protein Isoforms (Isoforms)IBA 12/2019 - 10/2012
2	Glucose (Dextrose)FDA LinkGeneric 10/2012 - 09/2012
1	Sickle HemoglobinIBA 11/2022
1	Erythropoietin FDA Link 01/2021
1	HexokinaseIBA 01/2021
1	IronIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	InterferonsIBA 10/2020
1	CytokinesIBA 10/2020
1	Pharmaceutical PreparationsIBA 01/2019
1	CarcinogensIBA 07/2015
1	Glutamic Acid (Glutamate)FDA Link 07/2015
1	Lysine (L-Lysine)FDA Link 07/2015
1	Amino Acids FDA Link 09/2012
1	Serine (L-Serine)FDA Link 09/2012

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2017